Predict your next investment

Corporation
HEALTHCARE | Biotechnology
kiromic.com

See what CB Insights has to offer

Founded Year

2006

Stage

IPO | IPO

Total Raised

$130K

Date of IPO

10/16/2020

Market Cap

0.02B

Stock Price

1.10

About Kiromic

Kiromic (NASDAQ: KRBP) exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. The company's cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.

Kiromic Headquarter Location

7707 Fannin Suite 140

Houston, Texas, 77054,

United States

832-968-4888

Latest Kiromic News

Diamond Equity Research Initiates Coverage on Kiromic BioPharma, Inc. (NASDAQ: KRBP)

Dec 22, 2021

New York, New York, UNITED STATES NEW YORK, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Kiromic BioPharma, Inc. (NASDAQ:KRBP). The in-depth 24-page initiation report includes detailed information on the Kiromic BioPharma Inc.’s business model, services, industry, valuation, management, and risks. The full research report is available  here . Highlights from the report include: Large Market Opportunity Diamond AI: Differentiating Factor - One of the major limitations of cancer immunotherapy has been identifying the tumor-specific antigens (TSAs) that are solely expressed by tumor cells allowing the cell therapies to target and destroy the tumor cells. Identifying TSAs with high specificity is the key to enhancing the safety and efficacy of cancer immunotherapy. Kiromic’s Diamond AI platform can potentially drastically reduce the difficulty in identifying clinically significant biomarkers using big data science and over a billion data points compressing man years and billions of dollars spent on drug development. Diamond generates a prioritized list of cancer immunological targets for T cells and B cells. While the targets identified for the current pipeline of therapies have yet to prove efficacy and safety in clinical trials, initial encouraging results from preclinical trials and the pilot phase 1 data of the company’s cancer vaccine candidate provide encouraging data of Diamond’s ability to identify TSAs with high specificity. Solid Tumors: High Unmet Need - The use of reductionist approaches to cancer chemotherapies and recently with immunotherapies for solid tumors have produced an outcome failure rate of 90% (±5) in the past few decades. With mutation rates exceeding 200 in selective forms of solid tumors, it has become increasingly difficult to treat solid tumors in chaotic cancer environments. Even the recent success in CAR-T immunotherapies has been observed only in different forms of blood cancers, which are easier to study than solid tumors. While Solid tumors account for over 85% of all cancer cases representing a multi-billion-dollar market, there is a huge unmet need for an effective treatment for solid tumors. A Promising Pipeline of Next-Generation Immunotherapies - Kiromic has created a promising pipeline of allogeneic CAR-T therapies using the Gamma Delta approach which is expected to overcome the challenges previously observed in both autologous and allogeneic CAR-T therapies. The company’s lead therapy candidate is a cancer vaccine that has recently exhibited promising results in its pilot phase 1 clinical trial. Kiromic has concentrated its efforts on developing next-generation immunotherapies with a differentiated approach to treating various forms of solid tumors. Valuation Valuation - Kiromic is targeting a market with high unmet needs. We believe the company’s next-generation AI-based immunotherapies coupled with a large market provides opportunity. Assuming positive data, we model the approval and commercialization in FY2027. With over 57,000 annual cases just in the U.S. and 5 years overall survival rate of just 10%, pancreatic cancer is currently being treated with chemotherapies and targeted therapies with minimal success provide a huge and untapped market. Based on our assumptions, we have valued Kiromic BioPharma at $6.70 per share, contingent on successful execution by the company. Kiromic BioPharma, Inc. Kiromic BioPharma leverages AI-based technology to develop next-generation immunotherapies for solid tumors. The company has concentrated its efforts on developing allogeneic CAR-T therapies using the Gamma Delta approach. Kiromic’s lead therapy candidate, KiroVax is a cancer vaccine that has exhibited encouraging results in the pilot phase 1 study. For more information, visit https://ir.kiromic.com . About Diamond Equity Research Diamond Equity Research is a leading equity research and corporate access firm focused on small capitalization companies. Diamond Equity Research is an approved sell-side provider on major institutional investor platforms including Factset, Morningstar, and Thomson One. For more information, visit  https://www.diamondequityresearch.com . Disclosures: Diamond Equity Research LLC is being compensated by Kiromic BioPharma, Inc. for producing research materials regarding Kiromic BioPharma, Inc. and its securities, which is meant to subsidize the high cost of creating the report and monitoring the security, however the views in the report reflect that of Diamond Equity Research. All payments are received upfront and are billed for an annual or semi-annual research engagement. As of 12/22/2021 the issuer had paid us $35,000 for our company sponsored research services, which commenced 11/17/2021 and is billed annually. Diamond Equity Research LLC may be compensated for non-research related services, including presenting at Diamond Equity Research investment conferences, press releases and other additional services. The non-research related service cost is dependent on the company, but usually do not exceed $5,000. The issuer has not paid us for non-research related services as of 12/22/21. Issuers are not required to engage us for these additional services. Additional fees may have accrued since then. Although Diamond Equity Research company sponsored reports are based on publicly available information and although no investment recommendations are made within our company sponsored research reports, given the small capitalization nature of the companies we cover we have adopted an internal trading procedure around the public companies by whom we are engaged, with investors able to find such policy on our website public disclosures page . This report and press release do not consider individual circumstances and does not take into consideration individual investor preferences. Statements within this report may constitute forward-looking statements, these statements involve many risk factors and general uncertainties around the business, industry, and macroeconomic environment. Investors need to be aware of the high degree of risk in small capitalization equities including the complete loss of their investment. Investors can find various risk factors in the initiation report and in the 10K filings for Kiromic BioPharma, Inc. Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Kiromic

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kiromic is included in 3 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Kiromic Patents

Kiromic has filed 8 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Transcription factors
  • Antineoplastic drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/13/2017

7/21/2020

Clusters of differentiation, Transcription factors, Experimental cancer drugs, Antineoplastic drugs, Lymphoma

Grant

Application Date

3/13/2017

Grant Date

7/21/2020

Title

Related Topics

Clusters of differentiation, Transcription factors, Experimental cancer drugs, Antineoplastic drugs, Lymphoma

Status

Grant

Kiromic Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kiromic Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.